Back to workflow browser

First-pass extracted concept

NIA-AA Research Framework

Candidate: workflow template1 source documents4 linked claims1 workflow observations3 stage observations
Jump to workflow stagesJump to workflow logicJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

National Institute on Aging and Alzheimer's Association Research Framework

Workflow Stage Observations

Stage 1functional characterizationSource 1DOIPubMed

Biomarker-based biological classification

Why this stage exists: This stage shifts Alzheimer's disease definition in living people from a syndromal to a biological construct for research use.

Selection basis: Classify biomarkers by the pathologic process measured: beta-amyloid deposition, pathologic tau, and neurodegeneration.

Advance criteria: Obtain biomarker evidence that can document underlying pathologic processes in vivo or postmortem.

Enriches for: biological disease definition, pathologic process assignment

Stage 2secondary characterizationSource 1DOIPubMed

Cognitive staging

Why this stage exists: After biological definition, cognitive staging characterizes severity without making symptoms the basis of diagnosis.

Selection basis: Stage severity of cognitive impairment using continuous measures or categorical schemes.

Higher fidelity: yes

Enriches for: cognitive severity, disease continuum placement

Preserves downstream axes: separation of biological definition from symptom severity

Stage 3decision gateSource 1DOIPubMed

Fit-for-purpose use decision

Why this stage exists: The framework explicitly warns against routine clinical use and against forcing biomarker requirements when they do not fit the study objective.

Selection basis: Determine whether biomarker-based classification is appropriate for the specific research goals.

Decision gate: Biomarker-based research should be applied only when fit for purpose and should not restrict alternative hypothesis-testing approaches.

Guards against: misuse in general medical practice, overgeneralization to all dementia research, counterproductive biomarker requirements

Workflow Logic

Workflow evidenceSource 1

Objective: Provide a common research framework for diagnosing and staging Alzheimer's disease biologically using biomarkers and relating pathologic processes to cognitive symptoms.

Why it works: The framework separates biological definition from clinical symptoms by classifying biomarkers according to the pathologic process they measure, creating a common language for hypothesis generation and testing.

Priority logic: Biological characterization by biomarkers is prioritized for research definition of Alzheimer's disease, while cognitive staging is layered on to describe severity and symptom progression.

Validation strategy: The framework is intended for observational and interventional research to test hypotheses about interactions among pathologic processes and cognitive symptoms.

Target properties: biological disease definition, pathologic process classification, cognitive staging, research cohort stratification

Target mechanisms: biomarker grouping by beta-amyloid deposition, biomarker grouping by pathologic tau, biomarker grouping by neurodegeneration, linking pathologic processes with cognitive symptoms

Target techniques: biomarker-based classification, imaging biomarkers, biofluid biomarkers, continuous and categorical cognitive staging

Evidence Snippets

This unifying update is labeled a "research framework" because its intended use is for observational and interventional research, not routine clinical care.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1framework definitionsupports2018Source 1DOIPubMed

The NIA-AA Research Framework defines Alzheimer's disease biologically by underlying pathologic processes documented by postmortem examination or in vivo biomarkers rather than by clinical symptoms.

Quoted textsource-backed
In the National Institute on Aging and Alzheimer's Association Research Framework, Alzheimer's disease (AD) is defined by its underlying pathologic processes that can be documented by postmortem examination or in vivo by biomarkers. The diagnosis is not based on the clinical consequences of the disease (i.e., symptoms/signs) in this research framework, which shifts the definition of AD in living people from a syndromal to a biological construct.
Claim 2intended use scopesupports2018Source 1DOIPubMed

The NIA-AA Research Framework is intended for observational and interventional research and is premature and inappropriate for general medical practice.

Quoted textsource-backed
This unifying update is labeled a "research framework" because its intended use is for observational and interventional research, not routine clinical care... it is premature and inappropriate to use this research framework in general medical practice.
Claim 3staging schemesupports2018Source 1DOIPubMed

The framework treats Alzheimer's disease as a continuum and describes both continuous cognitive measures and two categorical cognitive staging schemes, including a three-category syndromal scheme and a six-stage numeric scheme.

Quoted textsource-backed
We focus on AD as a continuum, and cognitive staging may be accomplished using continuous measures. However, we also outline two different categorical cognitive schemes for staging the severity of cognitive impairment: a scheme using three traditional syndromal categories and a six-stage numeric scheme.
Claim 4use limitationsupports2018Source 1DOIPubMed

Biomarker-based research under this framework should be used when fit for the specific research goals and should not restrict alternative non-biomarker approaches.

Quoted textsource-backed
this research framework should not be used to restrict alternative approaches to hypothesis testing that do not use biomarkers... biomarker-based research should not be considered a template for all research into age-related cognitive impairment and dementia; rather, it should be applied when it is fit for the purpose of the specific research goals of a study.